

European guidelines for quality assurance in cervical cancer for collecting samples for conventional and liquid-based

Cytopathology

18, 133-139

DOI: [10.1111/j.1365-2303.2007.00464.x](https://doi.org/10.1111/j.1365-2303.2007.00464.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	European guidelines on cervical screening. <i>Cytopathology</i> , 2007, 18, 211-212.	0.4	2
2	European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. <i>Cytopathology</i> , 2008, 19, 342-354.	0.4	141
3	Cytologists should be aware of these guidelines just as colposcopists should understand cytology. <i>Cytopathology</i> , 2008, 19, 340-341.	0.4	0
4	Human Papillomavirus in Cervical Cancer Screening: Important Role as Biomarker. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 810-817.	1.1	73
5	Cytologic Detection of Cervical Abnormalities Using Liquid-Based Compared With Conventional Cytology. <i>Obstetrics and Gynecology</i> , 2008, 112, 1327-1334.	1.2	45
6	Cervical Cytology Specimen Adequacy. <i>Journal of Lower Genital Tract Disease</i> , 2008, 12, 71-81.	0.9	41
7	Prevaccination Distribution of Human Papillomavirus Types in Women Attending at Cervical Cancer Screening in Belgium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 321-330.	1.1	53
8	Comparison of Liquid-Based Cytology With Conventional Cytology for Detection of Cervical Cancer Precursors. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1757.	3.8	205
9	Follow-up after treatment of cervical intraepithelial neoplasia by human papillomavirus genotyping. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 201, 17.e1-17.e8.	0.7	31
11	Lubricant, Mucus, and Other Contaminant Materials as a Potential Source of Interpretation Errors in ThinPrep Cervical Cytology. <i>Journal of Lower Genital Tract Disease</i> , 2010, 14, 22-28.	0.9	12
12	Age-specific patterns of unsatisfactory results for conventional Pap smears and liquid-based cytology: data from two randomised clinical trials. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2010, 117, 1067-1073.	1.1	31
13	Cervical Cytology Biobanking in Europe. <i>International Journal of Biological Markers</i> , 2010, 25, 117-125.	0.7	21
14	European Guidelines for Quality Assurance in Cervical Cancer Screening. Second Edition – Summary Document. <i>Annals of Oncology</i> , 2010, 21, 448-458.	0.6	461
15	Pregnancy outcome in patients treated with cervical conization for cervical intraepithelial neoplasia. <i>International Journal of Gynecology and Obstetrics</i> , 2011, 112, 225-228.	1.0	36
16	Cervical adenocarcinoma: Moving towards better prevention. <i>Vaccine</i> , 2011, 29, 9148-9158.	1.7	59
17	Type-specific HPV genotyping improves detection of recurrent high-grade cervical neoplasia after conisation. <i>International Journal of Cancer</i> , 2011, 129, 903-909.	2.3	50
18	Sexually Transmitted Diseases Treatment Guidelines, 2010. <i>Annals of Emergency Medicine</i> , 2011, 58, 67-68.	0.3	925
19	European guidelines for quality assurance in cervical histopathology. <i>Acta Oncologica</i> , 2011, 50, 611-620.	0.8	25

#	ARTICLE	IF	CITATIONS
20	Clinical Validation of a Type-Specific Real-Time Quantitative Human Papillomavirus PCR against the Performance of Hybrid Capture 2 for the Purpose of Cervical Cancer Screening. <i>Journal of Clinical Microbiology</i> , 2012, 50, 4073-4077.	1.8	41
21	Causes and Relevance of Unsatisfactory and Satisfactory but Limited Smears of Liquid-Based Compared With Conventional Cervical Cytology. <i>Archives of Pathology and Laboratory Medicine</i> , 2012, 136, 76-83.	1.2	40
22	ABC3 Part I: a review of the guidelines for terminology, classification and management of cervical cytology in England. <i>Cytopathology</i> , 2012, 23, 353-359.	0.4	8
23	Changes in type-specific human papillomavirus load predict progression to cervical cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 3096-3104.	1.6	48
24	Low cost versus other screening tests to detect cervical cancer or precancer in developing countries. <i>The Cochrane Library</i> , 2021, 2021, .	1.5	1
25	Liquid-based cervical cytology using ThinPrep technology: weighing the pros and cons in a cost-effectiveness analysis. <i>Cancer Causes and Control</i> , 2012, 23, 1323-1331.	0.8	21
27	Quality control in cervicovaginal cytology by cytohistological correlation. <i>Cytopathology</i> , 2013, 24, 33-38.	0.4	14
28	Creating awareness and facilitating cervical and breast cancer screening uptake through the use of a Community Health Worker: a pilot intervention study. <i>European Journal of Cancer Care</i> , 2013, 22, 107-116.	0.7	21
29	European Federation of Colposcopy quality standards Delphi consultation. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2013, 170, 255-258.	0.5	30
30	Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. <i>The Cochrane Library</i> , 2021, 2021, CD008054.	1.5	67
31	High-risk HPV testing on self-sampled versus clinician-collected specimens: A review on the clinical accuracy and impact on population attendance in cervical cancer screening. <i>International Journal of Cancer</i> , 2013, 132, 2223-2236.	2.3	210
32	Multiple Human Papillomavirus Infections with High Viral Loads Are Associated with Cervical Lesions but Do Not Differentiate Grades of Cervical Abnormalities. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1458-1464.	1.8	93
33	Transformation zone sampling rate used as a performance indicator for cervical liquid-based cytology sample-takers. <i>Cytopathology</i> , 2013, 24, 222-227.	0.4	2
34	Quality Indicators for Cervical Cancer Screening Programs. <i>International Journal of Reliable and Quality E-Healthcare</i> , 2014, 3, 19-37.	1.0	5
35	Clinical Evaluation of a GP5+/6+-Based Luminex Assay Having Full High-Risk Human Papillomavirus Genotyping Capability and an Internal Control. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3996-4002.	1.8	40
36	DIAGNOSTIC COLPOSCOPIC ACCURACY BY THE GYNOCULAR AND A STATIONARY COLPOSCOPE. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 181-187.	0.2	10
37	Follow-up strategies after treatment (large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): Impact of human papillomavirus (HPV) test. <i>The Cochrane Library</i> , 2015, 1, CD010757.	1.5	18
38	The implementation of an organised cervical screening programme in Poland: an analysis of the adherence to European guidelines. <i>BMC Cancer</i> , 2015, 15, 279.	1.1	27

#	ARTICLE	IF	CITATIONS
39	Retrospective Rescreening of Negative Cervical Cytology Samples Preceding Histologically Proven CIN2-3 and Squamous Cell Carcinoma: An Educational Opportunity to Understand and Prevent Laboratory Errors. <i>Acta Cytologica</i> , 2015, 59, 265-272.	0.7	5
40	Linear viral load increase of a single HPV type in women with multiple HPV infections predicts progression to cervical cancer. <i>International Journal of Cancer</i> , 2016, 139, 2021-2032.	2.3	33
41	The value of a transformation zone component in anal cytology to detect HSIL. <i>Cancer Cytopathology</i> , 2016, 124, 596-601.	1.4	12
43	Surveillance of effects of HPV vaccination in Belgium. <i>Cancer Epidemiology</i> , 2016, 41, 152-158.	0.8	20
44	Laboratory audit as part of the quality assessment of a primary HPV-screening program. <i>Journal of Clinical Virology</i> , 2016, 75, 33-36.	1.6	17
45	Human Papillomavirus Positivity in Women Undergoing Intrauterine Insemination Has a Negative Effect on Pregnancy Rates. <i>Gynecologic and Obstetric Investigation</i> , 2016, 81, 41-46.	0.7	36
46	Self-sampling to improve cervical cancer screening coverage in Switzerland: a randomised controlled trial. <i>British Journal of Cancer</i> , 2017, 116, 1382-1388.	2.9	18
47	Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel. <i>Journal of Clinical Microbiology</i> , 2017, 55, 3544-3551.	1.8	30
48	Quality assessment and improvement of "Unsatisfactory" liquid-based cervicovaginal papanicolaou smears. <i>Diagnostic Cytopathology</i> , 2017, 45, 873-877.	0.5	5
49	Analytic and Diagnostic Performances of Human Papillomavirus E6/E7 mRNA Test on up-to 11-Year-Old Liquid-Based Cervical Samples. A Biobank-Based Longitudinal Study. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1480.	1.8	9
50	VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples. <i>Journal of Clinical Virology</i> , 2018, 107, 52-56.	1.6	72
51	Prevalence of High-risk HPV in Postmenopausal Women with Benign Cervical Cytology "A Population-based Cohort Study. <i>Anticancer Research</i> , 2018, 38, 4221-4228.	0.5	8
52	Self- versus physician-collected samples for the follow-up of human papillomavirus-positive women in sub-Saharan Africa. <i>International Journal of Women's Health</i> , 2018, Volume 10, 187-194.	1.1	14
53	Using the VALGENT-3 framework to assess the clinical and analytical performance of the RIATOL qPCR HPV genotyping assay. <i>Journal of Clinical Virology</i> , 2019, 120, 57-62.	1.6	12
54	Efficacy of strategies to increase participation in cervical cancer screening: GPs offering self-sampling kits for HPV testing versus recommendations to have a pap smear taken - A randomised controlled trial. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2020, 9, 100194.	4.5	9
55	The cytological component of cervical cancer screening: causes of false negative and false positive results, and ways to avoid them. <i>Reproductive Endocrinology</i> , 2021, , 61-67.	0.0	0
56	National Data Analysis and Systematic Review for Human Resources for Cervical Cancer Screening in Japan. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 1695-1702.	0.5	2
57	Sexually Transmitted Infections Treatment Guidelines, 2021. <i>MMWR Recommendations and Reports</i> , 2021, 70, 1-187.	26.7	841

#	ARTICLE	IF	CITATIONS
58	Clinical and analytical evaluation of the RealTime High Risk HPV assay in Colli-Pee collected first-void urine using the VALHUDES protocol. <i>Gynecologic Oncology</i> , 2021, 162, 575-583.	0.6	27
59	Cervical Cytology Biobanks as a Resource for Molecular Epidemiology. <i>Methods in Molecular Biology</i> , 2011, 675, 279-298.	0.4	27
60	Comparison of EUS-guided conventional smear and liquid-based cytology in pancreatic lesions: A systematic review and meta-analysis. <i>Endoscopy International Open</i> , 2020, 08, E1611-E1622.	0.9	10
61	Comparative Assessment of a Self-sampling Device and Gynecologist Sampling for Cytology and HPV DNA Detection in a Rural and Low Resource Setting: Malaysian Experience. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016, 16, 8495-8501.	0.5	8
62	Assessment of the Reliability of a Novel Self-sampling Device for Performing Cervical Sampling in Malaysia. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 559-564.	0.5	5
63	Early Detection of Cervical Carcinomas – Finding an Overall Approach. <i>Deutsches A&#x0308;rztblatt International</i> , 2008, 105, 617-22.	0.6	18
64	Cervix uteri und Vagina. , 2011, , 97-143.		0
65	15 Optimale afname van cellen van de baarmoederhals voor cervixscreening. , 2013, , 199-206.		0
66	Female Genital Tract. <i>Cancer Treatment and Research</i> , 2014, 160, 241-272.	0.2	0
67	Mapping Population Health Management Roadmap into Cervical Cancer Screening Programs. <i>International Journal of Reliable and Quality E-Healthcare</i> , 2015, 4, 1-18.	1.0	7
68	Liquid Based Cytology Cervical Cancer Screening Program – Georgian Experience. <i>AIMS Medical Science</i> , 2016, 3, 272-277.	0.2	0
69	Modern Approach to Cervical Cancer Screening Program – Georgian Experience. <i>International Clinical Pathology Journal</i> , 2016, 2, .	0.1	0
70	Mapping Population Health Management Roadmap into Cervical Cancer Screening Programs. , 2017, , 960-980.		0
71	Population Health Management and Cervical Cancer Screening Programs. <i>Advances in Healthcare Information Systems and Administration Book Series</i> , 2017, , 1-31.	0.2	0
72	Quality Improvement and Laboratory Management for Cytopathology. , 2018, , 718-723.		0
73	Population Health Management and Cervical Cancer Screening Programs. , 2019, , 959-989.		0
74	Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recommendations and Reports</i> , 2015, 64, 1-137.	26.7	1,132
75	Cervical cancer and screening: knowledge, awareness and attitudes of women in Malta. <i>Journal of Preventive Medicine and Hygiene</i> , 2020, 61, E584-E592.	0.9	0

#	ARTICLE	IF	CITATIONS
76	Diagnostic accuracy for alternative cervical cancer screening strategies: A systematic review and meta-analysis. <i>Health Care for Women International</i> , 2024, 45, 323-362.	0.6	2
77	Importance of the Immune Microenvironment in the Spontaneous Regression of Cervical Squamous Intraepithelial Lesions (cSIL) and Implications for Immunotherapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 1432.	1.0	8
79	Clinical Performance of the RealTime High Risk HPV Assay on Self-Collected Vaginal Samples within the VALHUDES Framework. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	8
80	Validation of BD Onclarity HPV Assay on Vaginal Self-Samples versus Cervical Samples Using the VALHUDES Protocol. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 2177-2184.	1.1	11
81	Cervical cancer prevention and screening: a review of international clinical guidelines. <i>Russian Journal of Human Reproduction</i> , 2022, 28, 90.	0.1	0
82	The Significance of Cytology, Biopsy, and HPV Testing. , 2023, , 67-105.		0